Amato J. Giaccia
Publications
- A low-carb diet kills tumor cells with a mutant p53 tumor suppressor gene: the Atkins diet suppresses tumor growth. Cell Cycle. 2013; (5): 718-9
- CTGF is a therapeutic target for metastatic melanoma. Oncogene. 2013
- Blood and bones: osteoblastic HIF signaling regulates erythropoiesis. Cell Cycle. 2012; (12): 2221-2
- Global alteration in gene expression profiles of deciduas from women with idiopathic recurrent pregnancy loss. Mol Hum Reprod. 2012; (9): 442-50
- Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer. Clin Cancer Res. 2012; (6): 1798-807
- Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial. Clin Cancer Res. 2012; (1): 301-7
- State of the science: an update on renal cell carcinoma. Mol Cancer Res. 2012; (7): 859-80
- The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell. 2012; (1): 63-74
- The mitochondrial citrate transporter, CIC, is essential for mitochondrial homeostasis. Oncotarget. 2012; (10): 1220-35
- VEGF-independent cell-autonomous functions of HIF-1α regulating oxygen consumption in fetal cartilage are critical for chondrocyte survival. J Bone Miner Res. 2012; (3): 596-609
- A central role for hypoxic signaling in cartilage, bone, and hematopoiesis. Curr Osteoporos Rep. 2011; (2): 46-52
- Basic Principles of Radiobiology Breast Surgical Techniques and Interdisciplinary Management. 2011: 799-812
- Control of lysyl oxidase activity through site-specific deuteration of lysine. Bioorg Med Chem Lett. 2011; (1): 255-8
- Double knockdown of prolyl hydroxylase and factor-inhibiting hypoxia-inducible factor with nonviral minicircle gene therapy enhances stem cell mobilization and angiogenesis after myocardial infarction. Circulation. 2011; (11 Suppl): S46-54
- Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov. 2011; (5): 351-64
- Hypoxia and senescence: the impact of oxygenation on tumor suppression. Mol Cancer Res. 2011; (5): 538-44
- Lack of HIF-2α in limb bud mesenchyme causes a modest and transient delay of endochondral bone development. Nat Med. 2011; (1): 25-6; author reply 27-9
- SAR studies of 4-pyridyl heterocyclic anilines that selectively induce autophagic cell death in von Hippel-Lindau-deficient renal cell carcinoma cells. Bioorg Med Chem. 2011; (11): 3347-56
- Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med. 2011; (94): 94ra70
- Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res. 2011; (13): 4423-31
- VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKC{delta}-driven migration. Proc Natl Acad Sci U S A. 2011; (5): 1931-6
- 4-Pyridylanilinothiazoles that selectively target von Hippel-Lindau deficient renal cell carcinoma cells by inducing autophagic cell death. J Med Chem. 2010; (2): 787-97
- AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res. 2010; (19): 7570-9
- DNA Damage and Repair Textbook of Radiation Oncology, 3rd Edition. 2010: 31-39
- Hypoxia in models of lung cancer: implications for targeted therapeutics. Clin Cancer Res. 2010; (19): 4843-52
- Hypoxia, Gene Expression and Metastasis The Tumor Microenvironment. 2010: 43-58
- Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev. 2010; (2): 285-93
- Hypoxia-inducible factor-1 activation in nonhypoxic conditions: the essential role of mitochondrial-derived reactive oxygen species. Mol Biol Cell. 2010; (18): 3247-57
- MiR-210--micromanager of the hypoxia pathway. Trends Mol Med. 2010; (5): 230-7
- PHD2 in tumour angiogenesis. Br J Cancer. 2010; (1): 1-5
- Prematastatic Niches Tumor Microenvironment. 2010: 161-182
- Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth. Mol Cell Biol. 2010; (1): 344-53
- Renal oxygenation suppresses VHL loss-induced senescence that is caused by increased sensitivity to oxidative stress. Mol Cell Biol. 2010; (19): 4595-603
- Role of carcinoma-associated fibroblasts and hypoxia in tumor progression Diverse Effects of Hypoxia on Tumor Progression. 2010: 31-45
- Role of carcinoma-associated fibroblasts and hypoxia in tumor progression. Curr Top Microbiol Immunol. 2010: 31-45
- Targeting cancer cells through autophagy for anticancer therapy. Curr Opin Cell Biol. 2010; (2): 246-51
- The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways. PLoS One. 2010; (3): e9633
- Toxoplasma gondii activates hypoxia-inducible factor (HIF) by stabilizing the HIF-1alpha subunit via type I activin-like receptor kinase receptor signaling. J Biol Chem. 2010; (35): 26852-60
- ATM activation and signaling under hypoxic conditions. Mol Cell Biol. 2009; (2): 526-37
- Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood. 2009; (22): 5568-74
- Bioreductively activated lysyl oxidase inhibitors against hypoxic tumours. ChemMedChem. 2009; (10): 1590-4
- Bringing H2AX into the angiogenesis family. Cancer Cell. 2009; (6): 459-61
- Hypoxia, angiogenesis and oral cancer metastasis Oral Cancer Metastasis. 2009: 299-321
- Hypoxia-Mediated Signaling Pathways Handbook of Cell Signaling, 2nd Edition. 2009: 2241-2245
- Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 2009; (1): 35-44
- Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell. 2009; (6): 856-67
- Inhibition of histone deacetylase activity in reduced oxygen environment enhances the osteogenesis of mouse adipose-derived stromal cells. Tissue Eng Part A. 2009; (12): 3697-707
- Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009; (5): 891-906
- Pharmacologically increased tumor hypoxia can be measured by 18F-Fluoroazomycin arabinoside positron emission tomography and enhances tumor response to hypoxic cytotoxin PR-104. Clin Cancer Res. 2009; (23): 7170-4
- The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res. 2009; (3): 775-84
- Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell. 2009; (6): 527-38
- Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. J Clin Oncol. 2009; (26): 4281-6
- Molecular imaging of hypoxia-inducible factor 1 alpha and von Hippel-Lindau interaction in mice. Mol Imaging. 2008 May-Jun; (3): 139-46
- (2R)-[(4-Biphenylylsulfonyl)amino]-N-hydroxy-3-phenylpropionamide (BiPS), a matrix metalloprotease inhibitor, is a novel and potent activator of hypoxia-inducible factors. Mol Pharmacol. 2008; (1): 282-8
- A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell. 2008; (1): 90-102
- Hypoxia-inducible factor-1alpha stabilization in nonhypoxic conditions: role of oxidation and intracellular ascorbate depletion. Mol Biol Cell. 2008; (1): 86-94
- Notch1 is an effector of Akt and hypoxia in melanoma development. J Clin Invest. 2008; (11): 3660-70
- Ph.D. Training in cancer biology. Cancer Res. 2008; (22): 9122-4
- Principles of Radiation Oncology Principles & Practice of Oncology, 8th Edition. 2008: 307-327
- Short hairpin RNA interference therapy for ischemic heart disease. Circulation. 2008; (14 Suppl): S226-33
- Targeted therapy for the loss of von Hippel-Lindau in renal cell carcinoma: a novel molecule that induces autophagic cell death. Autophagy. 2008; (7): 944-6
- Targeting cancer cells by synthetic lethality: autophagy and VHL in cancer therapeutics. Cell Cycle. 2008; (19): 2987-90
- The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation. Mol Cell. 2008; (3): 303-14
- The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008; (4): 678-85
- Oxygen sensitivity of reporter genes: implications for preclinical imaging of tumor hypoxia. Mol Imaging. 2007 Jul-Aug; (4): 219-28
- Age decreases endothelial progenitor cell recruitment through decreases in hypoxia-inducible factor 1alpha stabilization during ischemia. Circulation. 2007; (24): 2818-29
- Energy regulation: HIF MXIes it up with the C-MYC powerhouse. Dev Cell. 2007; (6): 845-6
- Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 2007; (1): 167-75
- HIF gene expression in cancer therapy. Methods Enzymol. 2007: 323-45
- Hif-1alpha regulates differentiation of limb bud mesenchyme and joint development. J Cell Biol. 2007; (3): 451-64
- Hypoxia inducible factor-1alpha deficiency affects chondrogenesis of adipose-derived adult stromal cells. Tissue Eng. 2007; (6): 1159-71
- Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev. 2007; (2): 333-9
- Imaging tumoral hypoxia: oxygen concentrations and beyond. Oncology (Williston Park). 2007; (3): 368-76; discussion 377-8, 384
- In vitro expansion of adipose-derived adult stromal cells in hypoxia enhances early chondrogenesis. Tissue Eng. 2007; (12): 2981-93
- Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro. Mol Cell Biol. 2007; (3): 912-25
- Oxygen sensing and the DNA-damage response. Curr Opin Cell Biol. 2007; (6): 680-4
- Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells. Cancer Res. 2007; (12): 5896-905
- An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res. 2006; (5): 1507-14
- Checking in on hypoxia/reoxygenation. Cell Cycle. 2006; (12): 1304-7
- Comment on: osteopontin as toxic marker. Radiother Oncol. 2006; (2): 230; author reply 230-1
- Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 2006; (11): 5816-27
- DNA damage during reoxygenation elicits a Chk2-dependent checkpoint response. Mol Cell Biol. 2006; (5): 1598-609
- Effect of reduced oxygen tension on chondrogenesis and osteogenesis in adipose-derived mesenchymal cells. Am J Physiol Cell Physiol. 2006; (4): C1139-46
- Functional analysis of p53 binding under differential stresses. Mol Cell Biol. 2006; (19): 7030-45
- Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 2006; (3): e47
- Genome-wide analysis of p53 under hypoxic conditions. Mol Cell Biol. 2006; (9): 3492-504
- HIF1alpha delays premature senescence through the activation of MIF. Genes Dev. 2006; (24): 3366-71
- Hypoxia in Cancer Apoptosis and Cancer Chemotherapy: From Cutting-edge Science to Novel Therapeutic Concepts. 2006: 777-798
- Hypoxia-inducible factor-1 and p53: friends, acquaintances, or strangers? Clin Cancer Res. 2006; (17): 5007-9
- Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol. 2006; (10): 699-757
- Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006; (7088): 1222-6
- Lysyl oxidase mediates hypoxic control of metastasis. Cancer Res. 2006; (21): 10238-41
- Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. Cancer Res. 2006; (3): 1561-9
- Plasma osteopontin is an independent prognostic marker for head and neck cancers. J Clin Oncol. 2006; (33): 5291-7
- The host cell transcription factor hypoxia-inducible factor 1 is required for Toxoplasma gondii growth and survival at physiological oxygen levels. Cell Microbiol. 2006; (2): 339-52
- The roles of Chk 1 and Chk 2 in hypoxia and reoxygenation. Cancer Lett. 2006; (2): 161-7
- Radiobiology for the Radiologist, Sixth Edition Radiobiology for the Radiologist, Sixth Edition. 2006
- A noninvasive approach for assessing tumor hypoxia in xenografts: developing a urinary marker for hypoxia. Cancer Res. 2005; (14): 6151-8
- Adaptive myogenesis under hypoxia. Mol Cell Biol. 2005; (8): 3040-55
- Angiogenesis is required for successful bone induction during distraction osteogenesis. J Bone Miner Res. 2005; (7): 1114-24
- Anoxia is necessary for tumor cell toxicity caused by a low-oxygen environment. Cancer Res. 2005; (8): 3171-8
- Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha. Mol Cell Biol. 2005; (15): 6415-26
- Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol. 2005; (35): 8932-41
- Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene. 2005; (43): 6555-63
- OS-9 interacts with hypoxia-inducible factor 1alpha and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1alpha. Mol Cell. 2005; (4): 503-12
- The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell. 2005; (6): 443-54
- The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality. Nat Genet. 2005; (2): 145-52
- The role of p53 in hypoxia-induced apoptosis. Biochem Biophys Res Commun. 2005; (3): 718-25
- The role of ATM and ATR in the cellular response to hypoxia and re-oxygenation. DNA Repair (Amst). 2004 Aug-Sep; (8-9): 1117-22
- Hypoxic gene expression and metastasis. Cancer Metastasis Rev. 2004 Aug-Dec; (3-4): 293-310
- Dead cells don't form tumors: HIF-dependent cytotoxins. Cell Cycle. 2004; (2): 160-3
- Deletion of Vhlh in chondrocytes reduces cell proliferation and increases matrix deposition during growth plate development. Development. 2004; (10): 2497-508
- Developmental response to hypoxia. FASEB J. 2004; (12): 1348-65
- Distinct aerobic and hypoxic mechanisms of HIF-alpha regulation by CSN5. Genes Dev. 2004; (7): 739-44
- Identification of hypoxia-regulated proteins in head and neck cancer by proteomic and tissue array profiling. Cancer Res. 2004; (20): 7302-10
- Inhibition of ATR leads to increased sensitivity to hypoxia/reoxygenation. Cancer Res. 2004; (18): 6556-62
- JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell. 2004; (6): 781-94
- Oxygen-dependent regulation of adipogenesis. Methods Enzymol. 2004: 387-95
- Proceedings of the Oxygen Homeostasis/Hypoxia Meeting. Cancer Res. 2004; (9): 3350-6
- Radiation oncology: a century of achievements. Nat Rev Cancer. 2004; (9): 737-47
- Stem cell differentiation. Nat Biotechnol. 2004; (7): 804-5; author reply 805-6
- The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease. Genes Dev. 2004; (18): 2183-94
- The hypoxic tumor microenvironment and gene expression. Semin Radiat Oncol. 2004; (3): 207-14
- The use of plasma surface-enhanced laser desorption/ionization time-of-flight mass spectrometry proteomic patterns for detection of head and neck squamous cell cancers. Clin Cancer Res. 2004; (14): 4806-12
- Topical treatment with inhibitors of the phosphatidylinositol 3'-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Cancer Res. 2004; (7): 2552-60
- Transient changes in oxygen tension inhibit osteogenic differentiation and Runx2 expression in osteoblasts. J Biol Chem. 2004; (38): 40007-16
- XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res. 2004; (17): 5943-7
- ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation. J Biol Chem. 2003; (14): 12207-13
- Comparison of hypoxia-induced replication arrest with hydroxyurea and aphidicolin-induced arrest. Mutat Res. 2003; (1-2): 205-13
- HIF-1 as a target for drug development. Nat Rev Drug Discov. 2003; (10): 803-11
- HIF-alpha, a gender independent transcription factor. Clin Cancer Res. 2003; (7): 2391-3
- Hypoxia-Mediated Signaling Pathways Handbook of Cell Signaling. 2003: 277-282
- Hypoxia-induced gene expression occurs solely through the action of hypoxia-inducible factor 1alpha (HIF-1alpha): role of cytoplasmic trapping of HIF-2alpha. Mol Cell Biol. 2003; (14): 4959-71
- Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res. 2003; (1): 59-67
- Investigating hypoxic tumor physiology through gene expression patterns. Oncogene. 2003; (37): 5907-14
- Therapeutic exploitation of the physiological and molecular genetic alterations in head and neck cancer. Clin Cancer Res. 2003; (12): 4287-95
- Tumor deprivation of oxygen and tumor suppressor gene function. Methods Mol Biol. 2003: 485-504
- Hypoxia-inducible regulation of a prodrug-activating enzyme for tumor-specific gene therapy. Neoplasia. 2002 Jan-Feb; (1): 40-8
- Antiangiogenic therapy and p53. Science. 2002; (5581): 471; discussion 471
- Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther. 2002; (4): 291-6
- Effects of perillyl alcohol on melanoma in the TPras mouse model. Cancer Epidemiol Biomarkers Prev. 2002; (6): 573-9
- Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell. 2002; (2): 139-48
- Genetic Basis of Altered Responsiveness of Cancer Cells to Their Microenvironment Oncogene Directed Therapies. 2002: 113-129
- Hypoxia and Cell Cycle Cell Cycle Checkpoints and Cancer. 2002: 143-154
- Hypoxia links ATR and p53 through replication arrest. Mol Cell Biol. 2002; (6): 1834-43
- Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stra13: a mechanism for regulation of adipogenesis by hypoxia. Dev Cell. 2002; (3): 331-41
- Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol. 2002; (20): 7004-14
- Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha. J Biol Chem. 2002; (42): 40112-7
- Genetic determinants that influence hypoxia-induced apoptosis. Novartis Found Symp. 2001: 115-28; discussion 128-32
- Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res. 2001; (6): 2429-33
- Hypoxia regulates insulin-like growth factor-binding protein 1 in human fetal hepatocytes in primary culture: suggestive molecular mechanisms for in utero fetal growth restriction caused by uteroplacental insufficiency. J Clin Endocrinol Metab. 2001; (6): 2653-9
- Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol. 2001; (4): 1297-310
- Tumor hypoxia, the physiological link between Trousseau's syndrome (carcinoma-induced coagulopathy) and metastasis. Cancer Res. 2001; (3): 795-8
- p21(Cip1) and p27(Kip1) regulate cell cycle reentry after hypoxic stress but are not necessary for hypoxia-induced arrest. Mol Cell Biol. 2001; (4): 1196-206
- Candidate genes for the hypoxic tumor phenotype. Cancer Res. 2000; (4): 883-7
- Caveolin 1-mediated regulation of receptor tyrosine kinase-associated phosphatidylinositol 3-kinase activity by ceramide. Mol Cell Biol. 2000; (5): 1507-14
- Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther. 2000; (6): 493-8
- Epigenetic regulation of gene expression in cervical cancer cells by the tumor microenvironment. Clin Cancer Res. 2000; (2): 480-7
- Genetically modified clostridium for gene therapy of tumors. Methods Mol Med. 2000: 413-8
- Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 2000; (4): 391-6
- Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor. Clin Cancer Res. 2000; (7): 2941-50
- Regulation of insulin-like growth factor-binding protein 1 by hypoxia and 3',5'-cyclic adenosine monophosphate is additive in HepG2 cells. J Clin Endocrinol Metab. 2000; (10): 3821-7
- Regulation of insulin-like growth factor-binding protein-1 by nitric oxide under hypoxic conditions. J Clin Endocrinol Metab. 2000; (8): 2714-21
- p53 checkpoint-defective cells are sensitive to X rays, but not hypoxia. Exp Cell Res. 2000; (1): 82-91
- p53 promotes selection for Fas-mediated apoptotic resistance. Cancer Res. 2000; (16): 4638-44
- A p53 and apoptotic independent role for p21waf1 in tumour response to radiation therapy. Oncogene. 1999; (47): 6540-5
- Activation of metallothionein gene expression by hypoxia involves metal response elements and metal transcription factor-1. Cancer Res. 1999; (6): 1315-22
- Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science. 1999; (5411): 156-9
- Chemotherapy, tumor microenvironment and apoptosis Apoptosis and Cancer Chemotherapy. 1999: 223-240
- Hypoxia and cAMP stimulate vascular endothelial growth factor (VEGF) in human endometrial stromal cells: potential relevance to menstruation and endometrial regeneration. J Clin Endocrinol Metab. 1999; (6): 2245-8
- Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation. Cancer Res. 1999; (24): 6046-51
- Hypoxic microenvironment within an embryo induces apoptosis and is essential for proper morphological development. Teratology. 1999; (4): 215-25
- Mitogen-activated protein kinase phosphatase-1 (MKP-1) expression is induced by low oxygen conditions found in solid tumor microenvironments. A candidate MKP for the inactivation of hypoxia-inducible stress-activated protein kinase/c-Jun N-terminal protein kinase activity. J Biol Chem. 1999; (18): 12890-7
- Multiple roles for myc deregulation in oncogenesis DNA Alternations in Cancer: Genetic and Epigenetic Changes. 1999: 105-119
- The influence of tumor hypoxia on malignant progression Tumor Hypoxia: Pathophysiology, Clinical Significance and Therapeutic Perspectives. 1999: 115-124
- Tumor hypoxia and the cell cycle: implications for malignant progression and response to therapy. Cancer J Sci Am. 1998 Jul-Aug; (4): 218-23
- Acidosis reduces neuronal apoptosis. Neuroreport. 1998; (5): 875-9
- Cancer therapy and tumor physiology. Science. 1998; (5347): 12-3
- Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy. Cancer Res. 1998; (9): 1779-84
- Heat shock protein 72 modulates pathways of stress-induced apoptosis. J Biol Chem. 1998; (27): 17147-53
- Highly conserved RNA sequences that are sensors of environmental stress. Mol Cell Biol. 1998; (12): 7371-82
- Hypoxia stimulates insulin-like growth factor binding protein 1 (IGFBP-1) gene expression in HepG2 cells: a possible model for IGFBP-1 expression in fetal hypoxia. Proc Natl Acad Sci U S A. 1998; (17): 10188-93
- Inhibition of the anti-apoptotic PI(3)K/Akt/Bad pathway by stress. Genes Dev. 1998; (13): 1941-6
- The E6 and E7 genes of human papilloma virus-type 16 protect primary astrocyte cultures from injury. Brain Res. 1998; (1-2): 10-6
- The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 1998; (19): 2973-83
- The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998; (7): 1408-16
- p53 mediates apoptosis induced by c-Myc activation in hypoxic or gamma irradiated fibroblasts. Cell Death Differ. 1998; (2): 141-7
- Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther. 1997; (8): 791-6
- Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood. 1997; (9): 3322-31
- Loss of p21Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism. Cancer Res. 1997; (21): 4703-6
- Protease Inhibitor TPCK represses Ha-ras (Val 12) transformation and nuclear factor-κ B activation Int J Oncology. 1997: 895-900
- Protease inhibitor TPCK represses Ha-ras (Val12) transformation and nuclear factor-kappa B activation. Int J Oncol. 1997; (5): 895-900
- Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. Cancer Res. 1997; (19): 4200-4
- Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis. Mol Cell Biol. 1997; (12): 7306-16
- Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia. Gene Ther. 1996; (2): 173-8
- Early response of SiHa human squamous carcinoma cells to hypoxic signals: Evidence of parallel activation of NF-kB and AP-1 transcriptional complexes Int J Oncol. 1996: 875-882
- Early responses of SiHa human squamous carcinoma cells to hypoxic signals. Int J Oncol. 1996; (5): 875-82
- Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996; (6560): 88-91
- Hypoxic Stress Proteins: Survival of the Fittest. Semin Radiat Oncol. 1996; (1): 46-58
- Mechanism of heat shock protein 72 induction in primary cultured astrocytes after oxygen-glucose deprivation. Neurol Res. 1996; (1): 64-72
- Modulation of c-Myc activity and apoptosis in vivo. Cancer Res. 1996; (19): 4315-9
- New directions for radiation biology research in cancer of the uterine cervix. J Natl Cancer Inst Monogr. 1996; (21): 131-9
- Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res. 1996; (15): 3436-40
- The DNA damage response in DNA-dependent protein kinase-deficient SCID mouse cells: replication protein A hyperphosphorylation and p53 induction. Proc Natl Acad Sci U S A. 1996; (24): 13825-30
- Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents. Cancer Res. 1995; (17): 3726-31
- Chemotherapeutic tumour targeting using clostridial spores. FEMS Microbiol Rev. 1995; (3): 357-64
- Mitogen-activated protein kinase acts as a negative regulator of the heat shock response in NIH3T3 cells. Cancer Res. 1995; (23): 5512-9
- Analysis of HSF-1 phosphorylation in A549 cells treated with a variety of stresses. Int J Hyperthermia. 1994 May-Jun; (3): 371-9
- Activators of protein kinase C selectively mediate cellular cytotoxicity to hypoxic cells and not aerobic cells. Int J Radiat Oncol Biol Phys. 1994; (2): 259-65
- Hypoxia causes the activation of nuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues. Cancer Res. 1994; (6): 1425-30
- Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol. 1994; (9): 6264-77
- Hypoxic activation of nuclear factor-kappa B is mediated by a Ras and Raf signaling pathway and does not involve MAP kinase (ERK1 or ERK2). Cancer Res. 1994; (20): 5273-9
- Increased cytotoxicity of chronic hypoxic cells by molecular inhibition of GRP78 induction. Int J Radiat Oncol Biol Phys. 1994; (3): 661-6
- Modulation of potassium channels by protein tyrosine kinase inhibitors. J Cell Physiol. 1994; (1): 142-8
- The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. Proc Natl Acad Sci U S A. 1994; (11): 5124-8
- The regulation of GRP78 and messenger RNA levels by hypoxia is modulated by protein kinase C activators and inhibitors. Radiat Res. 1994; (1 Suppl): S60-3
- Tumour hypoxia: the picture has changed in the 1990s. Int J Radiat Biol. 1994; (1): 95-102
- Heat sensitivity of bleomycin-sensitive CHO derivatives is not due to improper initialization of heat shock response. Int J Hyperthermia. 1993 Mar-Apr; (2): 275-84
- Activation of potassium channels by hypoxia and reoxygenation in the human lung adenocarcinoma cell line A549. J Cell Physiol. 1993; (2): 341-7
- Analysis of restriction enzyme-induced chromosomal aberrations by fluorescence in situ hybridization. Environ Mol Mutagen. 1993; (1): 26-33
- Chromosomal radiosensitivity at intrachromosomal telomeric sites. Genes Chromosomes Cancer. 1993; (1): 8-14
- Potassium-channel activation in response to low doses of gamma-irradiation involves reactive oxygen intermediates in nonexcitatory cells. Proc Natl Acad Sci U S A. 1993; (3): 908-12
- Activation of the heat shock transcription factor by hypoxia in normal and tumor cell lines in vivo and in vitro. Int J Radiat Oncol Biol Phys. 1992; (4): 891-7
- Characterization of a CHO cell line resistant to killing by the hypoxic cell cytotoxin SR 4233. Int J Radiat Oncol Biol Phys. 1992; (4): 681-4
- Differential expression of protein kinase C epsilon protein in lung cancer cell lines by ionising radiation. Br J Cancer. 1992; (5): 844-9
- The use of asymmetric-field inversion gel electrophoresis to predict tumor cell radiosensitivity. Radiother Oncol. 1992; (4): 231-8
- What role do glutathione S-transferases play in the cellular response to ionizing radiation? Int J Radiat Oncol Biol Phys. 1992; (4): 759-63
- Biochemical evidence for two different mechanisms for bleomycin-induced cell killing. Mutat Res. 1991; (2): 69-75
- Loss of the intrinsic heat resistance of human cells and changes in Mr 70,000 heat shock protein expression in human x hamster hybrids. Cancer Res. 1991; (10): 2636-41
- The hypersensitivity of the Chinese hamster ovary variant BL-10 to bleomycin killing is due to a lack of glutathione S-transferase-alpha activity. Cancer Res. 1991; (16): 4463-9
- The use of fluorescence in situ hybridisation combined with premature chromosome condensation for the identification of chromosome damage. Br J Cancer. 1991; (4): 517-21
- scid mutation in mice confers hypersensitivity to ionizing radiation and a deficiency in DNA double-strand break repair. Proc Natl Acad Sci U S A. 1991; (4): 1394-7
- Genetic and biochemical characterization of the CHO-UV-1 mutant defective in postreplication recovery of DNA. Cancer Res. 1990; (8): 2356-62
- Human chromosome 5 complements the DNA double-strand break-repair deficiency and gamma-ray sensitivity of the XR-1 hamster variant. Am J Hum Genet. 1990; (3): 459-69
- Increased sensitivity to killing by restriction enzymes in the XR-1 DNA double-strand break repair-deficient mutant. Mutat Res. 1990; (1): 67-76
- Measurement of the relative proportion of symmetrical and asymmetrical chromosome-type interchanges induced by gamma radiation in human-hamster hybrid cells. Radiat Res. 1990; (1): 105-7
- Use of fluorescent in situ hybridization to detect chromosomal rearrangements in somatic cell hybrids. Genes Chromosomes Cancer. 1990; (3): 248-51
- An asymmetric field inversion gel electrophoresis method for the separation of large DNA molecules. Anal Biochem. 1989; (1): 172-6
- Genetic analysis of XR-1 mutation in hamster and human hybrids. Somat Cell Mol Genet. 1989; (1): 71-7
- Isolation and characterization of glucose-6-phosphate dehydrogenase-deficient Chinese hamster cells derived from pure mutant colonies. Mutagenesis. 1989; (4): 259-64
- Molecular cloning of the breakpoint region on chromosome 6 in cutaneous malignant melanoma: evidence for deletion in the c-myb locus and translocation of a segment of chromosome 12. Oncogene. 1989; (10): 1201-5
- Cell-cycle-dependent repair of potentially lethal damage in the XR-1 gamma-ray-sensitive Chinese hamster ovary cell. Radiat Res. 1988; (2): 325-33
- Delayed mutation in Chinese hamster cells. Somat Cell Mol Genet. 1987; (1): 57-65
- Isolation and characterization of bleomycin-sensitive Chinese hamster ovary cells. Cancer Res. 1987; (6): 1588-92
- Cell cycle-dependent repair of double-strand DNA breaks in a gamma-ray-sensitive Chinese hamster cell. Somat Cell Mol Genet. 1985; (5): 485-91
- Timing of mutation-fixation events in ethyl methane sulfonate-treated Chinese hamster cells. Somat Cell Mol Genet. 1984; (4): 429-34
- Isolation of cell cycle-dependent gamma ray-sensitive Chinese hamster ovary cell. Somatic Cell Genet. 1983; (2): 165-73
Help
Trial Administration